Civilization Ventures

Oxford Cancer Analytics develops an AI-based platform for early cancer detection via blood testing. It analyzes liquid biopsy results from DNA, proteins, epigenetics, epidemiology, and medical history, enabling healthcare providers to identify cancers early and initiate curative treatment.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

Aikium is a biotechnology company that specializes in developing novel protein therapeutics for neuro-inflammation and oncology. It combines advancements in synthetic biology and deep learning to create unique, non-antibody scaffold proteins that specifically target and bind to disordered regions of proteins, offering innovative solutions for clients to effectively address disordered proteins.

Catena Biosciences specializes in biotechnology, offering protein conjugation services for building biological structures and facilitating medical research. Its proprietary technology enables the attachment of proteins with high selectivity, supporting innovation in autoimmune disorders, oncology, and vaccine development.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the obstacles posed by tumors. Through its innovative approach, OverT Bio aims to enhance the effectiveness and durability of immunotherapies, contributing to advancements in cancer identification and treatment within the healthcare sector.

Insamo operates a biotechnology platform designed to pioneer the discovery of membrane-permeable and orally available cyclic peptides, exhibiting antibody-like binding affinity. Its automated process combines molecular biology and parallel synthetic chemistry to rapidly identify preclinical candidates with favorable pharmacological properties, enabling healthcare professionals to enhance patient care by replacing injected or infused biologics with easily administered oral cyclic-peptide formulations.

Founded in 2021, Aperiam Bio specializes in protein engineering. It partners with enzyme engineers and distributors to create stabilized, solubilized, and catalytically optimized proteins using computer vision algorithms and deep learning optimization.

Founded in 2017, DermBiont is a biotechnology company based in Boston, Massachusetts. It specializes in developing skin microbiome therapeutics to treat and prevent various skin diseases, with a focus on fungal infections.

Range Biotechnologies develops translational proteomics tools to enable personalized health by precisely measuring multiple proteins across numerous samples, delivering insights into the mechanisms of disease and their evolution over time to support healthcare professionals.

Siren Biotechnology is a biotech company focused on developing innovative cancer treatments through a unique platform that integrates AAV gene therapy with cytokine immunotherapy. By combining these two transformative therapeutic approaches, Siren aims to address significant challenges in cancer treatment, such as delivery, efficacy, and toxicity. This novel modality seeks to enhance the elimination of tumor cells while simultaneously stimulating anti-tumor immunity, thereby offering a promising new strategy for cancer therapy. Through this integrated approach, Siren Biotechnology aspires to advance the effectiveness of cancer treatments and improve patient outcomes.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Sensible Biotechnologies is developing a cell-based design, optimization, and manufacturing platform to enable next-generation messenger RNA medicines. The platform integrates cell engineering, computational biology, and precision fermentation to create and manufacture high-quality mRNA constructs with reduced immunogenicity. In particular, it focuses on optimizing the production of vaccinia capping enzymes to improve the stability and translation of therapeutic mRNA, supporting the creation of vaccines and medicines that are more effective and accessible. The approach aims to streamline development from design to production, reducing time and cost in bringing mRNA therapies to patients.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Wyndly is a company that specializes in personalized allergy treatment and online care. It offers clinically tested therapies designed to provide long-term relief from allergies. Wyndly's expert providers work closely with clients to develop tailored treatment plans that address the root causes of allergies, which are often not effectively managed by traditional antihistamines and nasal sprays. The company's innovative approach includes the use of allergy drops, which aim to deliver a more affordable and convenient form of immunotherapy. Overall, Wyndly focuses on enhancing the quality of life for individuals suffering from allergies by offering effective, customized solutions.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Founded in 2017, DermBiont is a biotechnology company based in Boston, Massachusetts. It specializes in developing skin microbiome therapeutics to treat and prevent various skin diseases, with a focus on fungal infections.

Klivo Health is a health technology company focused on enhancing the quality of life for individuals with chronic diseases. The company operates a patient management platform designed to empower users to manage their health effectively. By providing real-time monitoring of medical conditions and facilitating the transmission of critical health data, such as blood glucose levels, Klivo Health enables healthcare professionals to achieve improved clinical outcomes. The platform also offers users access to information regarding clinical conditions and dietary guidance. Through its innovative approach, Klivo Health aims to add life to years rather than merely extending lifespan.

Founded in 2020, Teiko.bio is a Salt Lake City-based company that provides an immune profiling platform. This platform supports global clinical trials by offering blood preservation kits, cytometry panels, data reports, and tailored gating services. It enables clinicians to make informed decisions regarding patient response.

Oxford Cancer Analytics develops an AI-based platform for early cancer detection via blood testing. It analyzes liquid biopsy results from DNA, proteins, epigenetics, epidemiology, and medical history, enabling healthcare providers to identify cancers early and initiate curative treatment.

Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Catena Biosciences specializes in biotechnology, offering protein conjugation services for building biological structures and facilitating medical research. Its proprietary technology enables the attachment of proteins with high selectivity, supporting innovation in autoimmune disorders, oncology, and vaccine development.

uLab Systems Inc. is a technology company specializing in digital dental treatment planning for orthodontists. Established in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, uLab has developed a sophisticated software platform that allows orthodontists to create customized treatment plans and aligner movement strategies. The company's proprietary technology employs artificial intelligence and fully automated features, enabling orthodontists to efficiently generate chairside treatment plans in under five minutes. This innovation not only streamlines the treatment process but also helps in reducing lab fees and expediting the delivery of custom aligners. Through its solutions, uLab Systems enhances the efficiency and effectiveness of orthodontic care.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Kit.com develops at-home health testing kits and related services to make preventative health testing available across industries. Its kits provide comprehensive remote health testing to track patients' health and offer a safe, convenient alternative to in-person doctor and laboratory visits. The company serves insurers and telehealth providers by enabling tests to be conducted remotely, integrating into care programs and supporting ongoing health monitoring.

R-Zero specializes in smart building technology, providing real-time insights to optimize indoor spaces. Their solutions include Indoor Air Quality (IAQ) monitoring, energy-efficient HVAC systems, space utilization sensors, and occupancy-based controls. The platform is user-friendly, secure, scalable, and helps prepare buildings for future challenges.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Fluent BioSciences is a life science technology company focused on single-cell molecular analysis, eliminating the need for complex microfluidic instrumentation. The company’s proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions. This innovative approach allows for sensitive and unbiased preparation of proteins and nucleic acids, enhancing sequencing applications. By making single-cell and molecular analysis more accessible, Fluent BioSciences enables a broader range of researchers in biotechnology, pharmaceuticals, and academic institutions to conduct advanced analyses, thereby expanding market opportunities within the life sciences field.

Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Gali Health, Inc. is a health technology company based in San Francisco, California, founded in 2015. The company has developed a mobile application called Gali, which serves as a personal health assistant aimed at individuals with chronic conditions. Gali leverages collective intelligence and artificial intelligence to analyze health data, providing users with personalized support regarding medical, lifestyle, and psychological aspects of managing their health. The platform focuses on empowering users by crowdsourcing health information and delivering medically-validated insights, enabling proactive health management. Gali Health's mission is to ensure that individuals dealing with chronic illnesses do not feel isolated or powerless, advancing consumer-driven healthcare through innovative technology.

Founded in 2017, DermBiont is a biotechnology company based in Boston, Massachusetts. It specializes in developing skin microbiome therapeutics to treat and prevent various skin diseases, with a focus on fungal infections.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Wild Earth is a technology-driven pet food company that develops plant-based, clean-protein diets for pets. It aims to provide healthier nutrition that is more humane and environmentally sustainable than conventional pet foods. Founded in 2017 and headquartered in Berkeley, California, Wild Earth emphasizes science-based formulations to meet pets' nutritional needs while reducing environmental impact.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

Qulab Inc. is a Los Angeles-based company founded in 2017 that specializes in automating drug design processes. By integrating advanced technologies such as computational chemistry, artificial intelligence, and quantum computing, Qulab aims to transform research and development in the chemical and pharmaceutical sectors. The company's innovative approach streamlines the design of small molecule medications, enhancing efficiency and accuracy in the drug development pipeline.

uLab Systems Inc. is a technology company specializing in digital dental treatment planning for orthodontists. Established in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, uLab has developed a sophisticated software platform that allows orthodontists to create customized treatment plans and aligner movement strategies. The company's proprietary technology employs artificial intelligence and fully automated features, enabling orthodontists to efficiently generate chairside treatment plans in under five minutes. This innovation not only streamlines the treatment process but also helps in reducing lab fees and expediting the delivery of custom aligners. Through its solutions, uLab Systems enhances the efficiency and effectiveness of orthodontic care.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Alveo Technologies develops infectious disease diagnostic devices and cloud-enabled platforms. Its be.well system includes nasal swabs, disposable cartridges, a handheld analyzer, and a cloud-based diagnostics platform. The system combines nucleic acid detection with molecular biochemistry to identify illnesses, integrating sample preparation, genetic material amplification, and real-time detection to identify diseases such as influenza A and B, COVID-19, and RSV. The company applies advances in sensing, microfluidics, and bioassays to create next-generation diagnostics that connect patients, healthcare professionals, and treatment providers, enabling earlier knowledge, faster action, and informed decisions. Its cloud-strengthened technology supports the collection of large datasets to track infectious disease outbreaks and link individuals with treatments, contributing to more personalized medicine and better health outcomes. Alveo Technologies was founded in 2014 and is based in Alameda, California.

Singular Bio, Inc. is a San Francisco-based company established in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a proprietary platform for single molecule analysis of DNA, which enables highly sensitive detection of various common health conditions. Singular Bio’s technology combines advanced optical methods with custom molecular biology and chemistry, allowing for cost-effective and rapid screening processes. The company's mission is to broaden access to essential healthcare information by making advanced genetic testing widely available, ultimately facilitating early detection and improved health outcomes for diverse populations. As of June 2019, Singular Bio operates as a subsidiary of Invitae Corporation.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

uLab Systems Inc. is a technology company specializing in digital dental treatment planning for orthodontists. Established in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, uLab has developed a sophisticated software platform that allows orthodontists to create customized treatment plans and aligner movement strategies. The company's proprietary technology employs artificial intelligence and fully automated features, enabling orthodontists to efficiently generate chairside treatment plans in under five minutes. This innovation not only streamlines the treatment process but also helps in reducing lab fees and expediting the delivery of custom aligners. Through its solutions, uLab Systems enhances the efficiency and effectiveness of orthodontic care.

Manus Bio recreates plant processes in microorganisms using fermentation technology. This enables the production of natural ingredients such as flavors, fragrances, food ingredients, bio-pesticides, and pharmaceuticals, offering businesses affordable and sustainable solutions.

Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Founded in 2013, Lemonaid Health specializes in improving patient experience through advanced machine learning and AI. It offers direct-to-consumer telemedicine services, utilizing evidence-based guidelines to provide affordable healthcare.

Rocket Pharmaceuticals is a biotechnology company focused on developing gene therapies for rare pediatric diseases. Its clinical-stage programs include treatments for Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Multerra Bio, Inc. is a medical device company based in San Francisco, California, established in 2015. The company specializes in developing handheld diagnostic devices that utilize a single consumable cartridge to facilitate a wide range of clinical tests. These devices are designed to assist medical professionals in performing various diagnostic activities efficiently. Through its innovative approach, Multerra Bio aims to enhance the accuracy and convenience of medical diagnostics.